N Inotsume, A Higashi, I Matsukane, S Chikazawa, M Nakano, I Matsuda
{"title":"脑瘫患者丹曲林血药浓度与日剂量的关系。","authors":"N Inotsume, A Higashi, I Matsukane, S Chikazawa, M Nakano, I Matsuda","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Serum concentration of dantrolene and its active metabolite, 5-hydroxydantrolene were determined in 27 cerebral palsy patients. Correlation coefficients between the oral dose of dantrolene and serum levels of dantrolene and its major metabolite, 5-hydroxydantrolene were rather small in cerebral palsy patients. The mean half-times of dantrolene and 5-hydroxydantrolene were 3.41 (n = 6) and 4.00 (n = 5) hours, respectively. These values were about a half of those reported earlier [Lietman et al., 1974; Meyler et al., 1979; Flewellen et al., 1983]. The poor correlation between serum level and dose may be due to the variation in an extent of oral dantrolene availability.</p>","PeriodicalId":77932,"journal":{"name":"Pediatric pharmacology (New York, N.Y.)","volume":"5 4","pages":"253-9"},"PeriodicalIF":0.0000,"publicationDate":"1986-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Relationship between serum concentration and daily dose of dantrolene in cerebral palsy patients.\",\"authors\":\"N Inotsume, A Higashi, I Matsukane, S Chikazawa, M Nakano, I Matsuda\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Serum concentration of dantrolene and its active metabolite, 5-hydroxydantrolene were determined in 27 cerebral palsy patients. Correlation coefficients between the oral dose of dantrolene and serum levels of dantrolene and its major metabolite, 5-hydroxydantrolene were rather small in cerebral palsy patients. The mean half-times of dantrolene and 5-hydroxydantrolene were 3.41 (n = 6) and 4.00 (n = 5) hours, respectively. These values were about a half of those reported earlier [Lietman et al., 1974; Meyler et al., 1979; Flewellen et al., 1983]. The poor correlation between serum level and dose may be due to the variation in an extent of oral dantrolene availability.</p>\",\"PeriodicalId\":77932,\"journal\":{\"name\":\"Pediatric pharmacology (New York, N.Y.)\",\"volume\":\"5 4\",\"pages\":\"253-9\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1986-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric pharmacology (New York, N.Y.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric pharmacology (New York, N.Y.)","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
测定27例脑瘫患者血清丹曲林及其活性代谢物5-羟基丹曲林的浓度。脑瘫患者口服丹曲林剂量与血清中丹曲林及其主要代谢物5-羟基丹曲林水平的相关系数较小。丹曲洛烯和5-羟基丹曲洛烯的平均半衰期分别为3.41 (n = 6)和4.00 (n = 5) h。这些数值大约是早期报道的一半[Lietman et al., 1974;meyer et al., 1979;Flewellen et al., 1983]。血清水平与剂量之间的相关性较差,可能是由于口服丹曲林可利用程度的变化。
Relationship between serum concentration and daily dose of dantrolene in cerebral palsy patients.
Serum concentration of dantrolene and its active metabolite, 5-hydroxydantrolene were determined in 27 cerebral palsy patients. Correlation coefficients between the oral dose of dantrolene and serum levels of dantrolene and its major metabolite, 5-hydroxydantrolene were rather small in cerebral palsy patients. The mean half-times of dantrolene and 5-hydroxydantrolene were 3.41 (n = 6) and 4.00 (n = 5) hours, respectively. These values were about a half of those reported earlier [Lietman et al., 1974; Meyler et al., 1979; Flewellen et al., 1983]. The poor correlation between serum level and dose may be due to the variation in an extent of oral dantrolene availability.